Ursolvan

Quick links to important sections

Ursolvan

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ursolvan

Property Description
Active ingredient Ursodiol (Ursodeoxycholic Acid, UDCA)
Form Capsules or Tablets
Pharmacological class Hepatoprotective, Cholagogue, Litholytic agent
General purpose Supports liver function; modifies bile composition
Origin Semi-synthetic (Bile acid derivative)

What is Ursolvan and its Active Component?

Ursolvan is a prescription-only medicine containing the Single active ingredient Ursodiol, chemically known as Ursodeoxycholic Acid (UDCA). This medication is available for Oral administration in solid dosage forms, specifically standardized Capsules or compressed Tablets. The compound belongs to the class of Bile acid derivatives. While a trace amount is naturally found in human bile, the therapeutic agent used in Ursolvan is manufactured through a controlled Semi-synthetic process to ensure pharmaceutical consistency and purity.

Pharmacological Classification and General Purpose

Ursolvan is categorized as a Hepatoprotective agent, a Cholagogue (or Choleretic), and a Litholytic agent. These roles are clinically recognized for their combined effect on liver health and bile flow. This classification confirms the medicine's primary purpose is to help support the liver by managing harmful substances and strengthening liver cell structures.

As a Litholytic agent, its key function is to modify the saturation of cholesterol in bile, helping to keep bile fluid and prevent hardening. Its activity involves altering the physicochemical properties of bile. This confirms the drug's fundamental capability to alter the bile environment and aid in the proper passage of bile.

Compositional Identity: Single Agent in Solid Form

Ursolvan is defined as a monotherapy, ensuring that the entire therapeutic benefit is attributed solely to the Ursodiol component. The physical forms are achieved by combining the Ursodiol with essential inert excipients. These stabilizing components, such as Pregelatinized Starch, Magnesium Stearate, and Silicon Dioxide, are crucial to the Composition for ensuring the preparation's structural integrity and accurate delivery via the Oral route.

What side effects are possible with Ursolvan?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Ursodiol (Ursolvan) as classified by governmental regulatory authorities.

Adverse reactions are primarily observed in the gastrointestinal and hepatobiliary systems.

Frequency-Classified Adverse Reactions

The following frequencies are based on regulatory standards:

Classification Adverse Reaction System Organ Class
Common (ge 1/100 to < 1/10) Diarrhea, Loose stools, Pasty stools Gastrointestinal disorders
Very Rare (< 1/10,000) Gallstone calcification, Hepatic cirrhosis decompensation Hepatobiliary disorders

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions documented in official labels include the decompensation of hepatic cirrhosis in patients with pre-existing cirrhosis and the calcification of previously radiolucent gallstones during treatment. The occurrence of severe right upper abdominal pain is also noted as a potential sign of a serious issue.

Safety-related limitations require regular monitoring of liver function tests (including ALT, AST, and bilirubin) before and periodically throughout therapy. Ursodiol is restricted from use in patients experiencing acute inflammation of the gallbladder or biliary tract, as well as those with complete biliary tract occlusion.

Population-Specific Safety Notes

For patients with Primary Biliary Cholangitis (PBC), the clinical symptom of pruritus (itching) may temporarily worsen; this effect is typically noted at the beginning of treatment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Ursolvan (ursodiol) describes the drug's overdose profile as one with limited systemic toxicity. Serious life-threatening effects are considered unlikely because the intestinal absorption of ursodiol is known to decrease as the dose increases, thereby limiting systemic exposure.

The most frequently documented clinical manifestation of potential overdose is diarrhea, reflecting the drug’s effects within the gastrointestinal system. Treatment focuses on managing this symptom, as no specific antidote is known to exist. Management involves symptomatic and supportive treatment, including the mandatory restoration of fluid and electrolyte balance. Procedural measures may include the use of ion-exchange resins to bind bile acids in the intestines.

Patients are required to seek immediate medical attention for any suspected overdose and to contact a regional poison control center. Regulatory guidance specifically requires a dose reduction or discontinuation of therapy if persistent severe diarrhea occurs. Following a suspected overdose, liver function should be monitored as a standard observation requirement. Animal studies referenced in the label also noted signs such as vomiting, salivation, and ataxia at lethal doses.

Therapeutic Uses of Ursolvan

What Ursolvan Treats: Main Uses and Benefits

Ursolvan (ursodeoxycholic acid) is a therapeutic agent used to manage certain hepatobiliary conditions. Its primary uses are centered on the relief of symptoms and management of specific chronic conditions affecting the liver and bile ducts. This medication is indicated for the dissolution of radiolucent, noncalcified cholesterol gallstones in selected patients and the symptomatic treatment of Primary Biliary Cholangitis (PBC), a chronic liver disease. It may also be used for specific hepatobiliary disorders associated with cystic fibrosis in children.

The benefit of using this therapy is primarily to assist in managing disease progression and providing relief for associated symptoms, such as pruritus (itching) in PBC. The use of the drug in these therapeutic domains is supported by the regulatory approval process.

Quick Fact: Relief for Pruritus in PBC

“The goal of treatment is to improve serum liver tests and manage disease progression.”

Eligibility and Restrictions for Use

Ursolvan (ursodeoxycholic acid) is officially restricted based on patient status, hypersensitivity, and the condition of the biliary system, as defined in regulatory documents.

Eligibility Constraints

Classification Who Must Not Use Ursolvan (Contraindications)
Allergy Known hypersensitivity to bile acids or any component of the formulation.
Biliary Status Acute inflammation of the gallbladder or bile ducts; complete biliary tract occlusion (e.g., common or cystic duct blockage).
Gallstone Type Patients with radiopaque, calcified, or radiolucent bile pigment gallstones.
Organ Function Impaired contractility or a non-functioning gallbladder; frequent episodes of biliary colic.

Specific Populations and Restrictions

Ursolvan is generally not recommended for use during pregnancy, particularly in the first trimester, due to limited data. Women of childbearing potential must use reliable non-hormonal contraception during treatment, as hormonal contraceptives may counteract the drug's effect when dissolving gallstones. Use in the pediatric population is not established for all indications, though some regulatory bodies permit its use for specific hepatobiliary disorders associated with cystic fibrosis in children aged 6 years and older. Patients with severe liver or intestinal diseases that interfere with the bile acid cycle are also typically excluded.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Ursolvan (ursodiol) is based on official government regulatory classifications, detailing which co-administered substances alter the drug's activity or have their exposure modified by Ursolvan.

Interaction Type Interacting Substances Official Interaction Statement
Reduced Ursodiol Absorption Bile Acid Sequestering Agents (e.g., Cholestyramine) and Aluminum-based Antacids These preparations bind to Ursodiol in the gut, which inhibits its absorption and efficacy.
Administration Timing Rule Bile Acid Sequestering Agents; Aluminum-based Antacids Administration of these agents must be separated from the Ursodiol dose by at least two hours.
Pharmacodynamic Antagonism Estrogens (e.g., in oral contraceptives) and Lipid-lowering agents (e.g., Clofibrate) These products counteract the effect of Ursodiol by increasing cholesterol secretion into the bile.
Metabolic/Exposure Alteration Ciclosporin, Nitrendipine, Dapsone Ursodiol may reduce the exposure (AUC) of these drugs. This is related to Ursodiol’s documented effect on the expression of intestinal drug-metabolizing systems, including CYP3A4 and P-glycoprotein (P-gp).

The overall regulatory structure classifies these interactions by their effect: those requiring administration separation due to reduced absorption, those causing therapeutic antagonism, and those involving the altered systemic exposure of co-administered agents. These documented patterns establish constraints on co-administration for all listed substances.

Mechanism of Action

Ursolvan (Ursodiol) exerts its effect through three primary mechanistic domains that influence the chemical and cellular environment of the liver and bile.


Modulation of Bile Acid Chemistry

This domain explains how Ursodiol, a hydrophilic bile acid, acts as a competitive displacement agent within the bile acid pool. It replaces more harmful, hydrophobic bile acids, which, in turn, decreases the overall cholesterol saturation of the bile. This process favors the physical solubilization of solidified cholesterol.


Cellular Cytoprotection and Membrane Stabilization

This mechanism involves direct stabilization of the membranes of liver cells (hepatocytes and cholangiocytes). Ursodiol incorporates itself into these cell structures, including the mitochondrial membrane, inhibiting the opening of the Mitochondrial Permeability Transition (MPT) pore. This action suppresses the apoptotic pathway, leading to the inhibition of hepatocyte apoptosis caused by toxic bile components.


Hepatic Immunomodulation and Flow Stimulation

This domain covers two key actions: an immunomodulatory effect, where Ursodiol helps down-regulate the expression of certain immune markers (MHC Class I) on hepatocyte surfaces, and a choleretic action. The choleretic mechanism stimulates the liver to produce an enhanced, bicarbonate-rich bile flow, which promotes the secretion of cholestatic substances and supports the fluidity of biliary flow.

Dosage and Administration Information

How Ursolvan is Used: Official Administration Guidelines

Ursolvan (ursodeoxycholic acid) is prescribed as an oral medication, provided in standardized capsules or tablets. The administration of this medicine is based on precise, official protocols.

Administration Scope Procedural Instruction
Dosing Principle The total daily dose is calculated on a weight-based principle, specifically in milligrams per kilogram (mg/kg) of body weight. For Primary Biliary Cholangitis (PBC), the regimen is often 13–15 mg/kg/day.
Frequency & Timing The calculated daily dose is typically administered in divided doses throughout the day. For certain uses, the dose is taken with a meal, and a larger portion may be instructed to be taken at bedtime to optimize effect.
Course Duration Use is structured as an extended course; for PBC, treatment is considered long-term. For gallstone dissolution, the course may last up to two years.
Pediatric Use Official guidelines specify use and dosing calculation for pediatric patients diagnosed with hepatobiliary disorders associated with cystic fibrosis.
Missed Dose Rule If an administration is missed, the patient should resume the regular schedule with the next dose; a double dose should not be taken.

This protocol ensures that the medicine is used consistently and maintains the therapeutic principles defined in official documentation. The tablets and capsules should be swallowed whole with water.

Recent Clinical Evidence

Ursolvan is primarily studied for its use in Primary Biliary Cholangitis (PBC). Research includes randomized controlled trials (RCTs) and extensive long-term observational registry analyses. These studies explored outcomes related to long-term health, such as transplant-free survival (measuring mortality or the need for a liver transplant), and monitored changes in major biochemical markers like Alkaline Phosphatase and bilirubin. Findings from the long-term registry data show patterns related to the use of the compound being observed in studies examining survival without liver transplantation. However, findings for patient-reported outcomes, specifically fatigue, remain limited and mixed across different studies.

Research into Ursolvan for gallstone dissolution status was conducted through RCTs and prospective studies. These studies were applied in highly selected adult populations with non-calcified, radiolucent gallstones and examined the physical outcome of dissolution status as measured by imaging. Trials reported varying rates, with data showing patterns related to smaller stones being associated with higher measured dissolution rates. The results apply only to these specific populations studied under strict selection criteria.

Ursolvan use in hepatobiliary disorders associated with Cystic Fibrosis (CF) was evaluated in smaller clinical trials, primarily focusing on children and adolescents. Studies monitored changes in key liver function markers and explored the evolution of liver disease metrics. Reported outcomes often showed an association with changes in liver lab markers over the study period.

The evidence base contains limitations and gaps. For example, some early PBC RCTs were generally not able to definitively measure differences in hard long-term endpoints. Furthermore, data for certain groups, such as adults with CF-related liver disease, remain insufficient. Data are still emerging regarding the continuation of the observed effect once the compound is stopped, particularly the long-term patterns of gallstone recurrence.

Frequently Asked Questions (FAQ)

Common questions about Ursolvan (FAQ)


Q: What is the mechanism by which Ursolvan helps in long-term liver diseases?

According to official regulatory documents, Ursodiol supports the liver through several mechanisms. It stabilizes the cell membranes of the liver, which helps protect them from damage caused by toxic bile components. Additionally, it stimulates the liver to produce a richer bile flow, which assists in clearing out harmful substances.


Q: Is Ursolvan intended as a short-term or long-term medication?

The duration of use depends on the specific condition being treated, as indicated in the official product information. For chronic liver conditions like Primary Biliary Cholangitis (PBC), treatment is typically considered long-term. For conditions requiring gallstone dissolution, the course is an extended one that may last up to two years.


Q: Are there any serious or rare side effects associated with Ursolvan use?

Official regulatory documents list all reported adverse reactions. While most side effects are common and mild, very rare and serious effects include the potential for gallstones to calcify (harden) during treatment. Additionally, in patients with pre-existing advanced liver disease, a worsening (decompensation) of the liver condition has been reported as a very rare effect.


Q: Can Ursolvan cause changes in liver enzyme levels, and is this common?

Regulatory documents indicate that Ursodiol is associated with a decrease in liver enzyme levels in studies involving patients with liver disease. However, to maintain safety, official guidelines require routine monitoring of key liver enzymes, such as AST and ALT, at the start of therapy and periodically thereafter.


Q: Can Ursolvan be used while breastfeeding?

Official product information does not definitively state whether Ursodiol is transferred into human milk. Therefore, due to the general caution required with medication use during this period, patients are generally advised to discuss the use of any medication while breastfeeding with their healthcare provider.


Q: Is Ursolvan ever prescribed for children, and for what conditions?

Yes, official regulatory guidelines specify the drug’s use and dosing calculations for pediatric patients. It is used to treat specific hepatobiliary disorders (conditions affecting the liver and bile ducts) that are associated with cystic fibrosis.


Q: What happens if Ursolvan treatment is stopped before the condition is fully resolved?

Discontinuation of treatment may mean that the medical condition, such as gallstones, remains unresolved. For those who successfully dissolve their gallstones, regulatory documents note that the recurrence of stones has been observed after stopping the bile acid therapy.


Q: Why might a doctor prescribe Ursolvan for a patient with cystic fibrosis?

Ursodiol has been authorized for use in the treatment of liver and bile duct disorders specifically associated with cystic fibrosis (CF). This indication is based on clinical guidelines and the drug’s designation for this specific use.


Q: What are the expected benefits of taking Ursolvan for a chronic liver disease?

Official data describes that studies for chronic liver disease, such as Primary Biliary Cholangitis (PBC), explore outcomes linked to long-term health. This includes monitoring for changes in key biochemical markers and parameters like transplant-free survival.


Q: How quickly can gallstones dissolve with Ursolvan treatment?

Gallstone dissolution using Ursodiol is documented as a lengthy process that requires many months of continuous therapy to be effective. Initial response or evidence of dissolution may begin to be observable after 3 to 6 months of treatment.


Q: Is there scientific evidence supporting the use of Ursolvan for primary biliary cholangitis (PBC)?

Yes, Ursodiol is extensively studied for this condition. It is primarily researched for Primary Biliary Cholangitis (PBC) through randomized controlled trials (RCTs) and long-term observational registry analyses to understand its effects on patient outcomes.


Q: Can Ursolvan help reduce the size of gallstones, or only dissolve them completely?

Clinical studies focus on achieving the dissolution status of the gallstones. Successful complete dissolution is the primary outcome, and it does not occur in all treated patients.


Q: Does Ursolvan affect cholesterol levels in the blood?

Ursodiol is documented to suppress the liver's production and secretion of cholesterol into the bile, and it can inhibit cholesterol absorption in the intestines. This action primarily reduces the cholesterol saturation of bile, which is necessary for its intended therapeutic effect.


Q: Is Ursolvan known to cause weight gain or weight loss?

Official adverse reaction reports from clinical trials have noted that weight gain was reported as an occasional symptom in patients with Primary Biliary Cholangitis (PBC).


Q: Are there different strengths or formulations of Ursolvan available?

Yes, Ursodiol is available in different strengths and dosage forms. Official regulatory documents list common strengths such as 250 mg and 500 mg tablets, and various capsule strengths.


Q: Why is Ursolvan usually taken with meals?

The medication is generally instructed to be administered with food as part of the recommended adult dosage regimen for conditions like Primary Biliary Cholangitis (PBC). This timing is defined in the official product information.


Q: Is Ursolvan considered a cure for chronic liver diseases, or a management treatment?

Ursodiol is indicated for the management of chronic cholestatic liver diseases like Primary Biliary Cholangitis (PBC). Official guidelines state that treatment for this condition is considered long-term management.


Q: What distinguishes Ursolvan from a medication used to reduce bile production?

Ursodiol is classified as a Cholagogue, or Choleretic, meaning one of its primary actions is to actively stimulate the liver. This action results in the production and secretion of an enhanced, bicarbonate-rich bile flow, not a reduction in production.


Q: Does Ursolvan have any known long-term side effects that develop over years of use?

Official labels list all adverse reactions observed in clinical trials, but do not provide specific data on how the frequency of common side effects may change over many years of continuous use. They do, however, list very rare, serious effects observed during treatment.


Q: Does Ursolvan have an effect on kidney function?

Official adverse reaction data from clinical trials for Ursodiol generally do not list a direct adverse effect on the kidneys. However, common side effects can include an increased risk for urinary tract infection.

How should Ursolvan be stored and disposed of?

The official storage and disposal guidelines for Ursolvan (Ursodiol) are established to maintain the product's quality and ensure public safety.

Official Storage and Disposal Requirements

Item Regulatory Requirement
Storage Temperature Store at mathbf20 C to 25 C (68 F to 77 F). Temperatures outside the permitted 15 C to 30 C range are prohibited.
Protection and Container Must be kept in a tightly closed container to protect the capsules or tablets from moisture.
Stability Note The unused half of a scored tablet, in specific formulations, must be used within 28 days.
Child Safety Rule Mandatory instruction to keep this medication out of the sight and reach of children.
Disposal Instructions Unused or expired product must be disposed of in accordance with local requirements.
Environmental Restriction It is prohibited to dispose of the medicine by flushing it down the toilet or throwing it into household waste.

These official statements define the required conditions to preserve the drug's stability, primarily by mandating controlled room temperature and moisture protection. They also set essential safety boundaries by requiring secured storage away from children and establishing environmentally responsible disposal practices for the unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ursolvan found in:

A-Z Index: